Filtered By:
Source: Thrombosis Research

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 221 results found since Jan 2013.

Protein S deficiency and Heerlen polymorphism in a Polish patient with acute myocardial infarction and previous venous thromboembolism
Protein S (PS) deficiency is an autosomal dominant disorder with a prevalence of less than 0.5% in the general European population and 2% to 12% in thrombophilic patients . This deficiency is most frequently caused by missense mutations (HGMD database, http://www.hgmd.org) in the PS gene (PROS1) located on chromosome 3 . Hereditary PS deficiency is an established risk factor for venous thromboembolism (VTE), and few reports have linked this thrombophilic factor with myocardial infarction (MI) or ischemic stroke .
Source: Thrombosis Research - October 10, 2013 Category: Hematology Authors: Ewa Wypasek, Daniel P. Potaczek, Joanna Płonka, Martine Alhenc-Gelas, Anetta Undas Tags: Letters to the Editors-in-Chief Source Type: research

Soluble P-selectin: The next step
It has long been recognised that platelets are implicated in both mortality and morbidity in the pathophysiology of a variety of conditions, including coronary artery disease , diabetes , cancer , stroke , and deep vein thrombosis . The success of aspirin in reducing thrombotic events, and the prognostic value of platelet volume, numbers and function in predicting cardiovascular death are further evidence of the importance of this cell. Consequently, the ability to accurately identify those subjects at risk of thrombosis, and possibly those experiencing an acute thrombotic event, is highly sought-after if risk reduction an...
Source: Thrombosis Research - November 11, 2013 Category: Hematology Authors: Andrew D. Blann Tags: Editorials Source Type: research

Differences in Thrombotic Risk Factors in Black and White Women with Adverse Pregnancy Outcome
Conclusions: Thrombotic risk factors differ significantly in white and black women with adverse pregnancy outcomes. Such differences highlight the importance of considering race separately when assessing thrombotic risk factors for adverse pregnancy outcomes.
Source: Thrombosis Research - November 18, 2013 Category: Hematology Authors: Claire S. Philipp, Ambarina S. Faiz, Michele G. Beckman, Althea Grant, Paula L. Bockenstedt, John A. Heit, Andra H. James, Roshni Kulkarni, Marilyn J. Manco-Johnson, Stephan Moll, Thomas L. Ortel Tags: Coagulation and Fibrinolysis Source Type: research

Risk factors for arterial thrombosis in antiphospholipid syndrome
Conclusions: Among APS patients those with ACL IgG antibodies, having livedo reticularis, and suffering from hypertension an hypercholesterolemia are at the increased risk of arterial thrombosis.
Source: Thrombosis Research - December 9, 2013 Category: Hematology Authors: Aleksandra Matyja-Bednarczyk, Jakub Swadźba, Teresa Iwaniec, Marek Sanak, Sylwia Dziedzina, Adam Ćmiel, Jacek Musiał Tags: Clinical Studies Source Type: research

CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention
Conclusions: High CHA2DS2-VASc score was the best predictor of thrombotic outcomes after PCI in a high risk AF population. High mHAS-BLED score was not predictive of bleeding events. More accurate, simple risk scores are needed.
Source: Thrombosis Research - January 24, 2014 Category: Hematology Authors: Marja K. Puurunen, Tuomas Kiviniemi, Axel Schlitt, Andrea Rubboli, Britta Dietrich, Pasi Karjalainen, Kai Nyman, Matti Niemelä, Gregory Y.H. Lip, K.E. Juhani Airaksinen Tags: Clinical Studies Source Type: research

MC-002 exhibits positive effects against platelets aggregation and endothelial dysfunction through thromboxane A2 inhibition
In conclusion, MC-002 exerted antiplatelet aggregation effect through TXA2 inhibition and relieved inflammatory injury of endothelial cells through NF-κB signal pathway.
Source: Thrombosis Research - February 12, 2014 Category: Hematology Authors: Weirong Fang, Jie Wei, Dan Han, Xi Chen, Guangwei He, Qiang Wu, Shaoxing Chu, Yunman Li Tags: Platelets and cell biology Source Type: research

Should women suffering from migraine with aura be screened for biological thrombophilia?: Results from a cross-sectional French study
Conclusion: FVL or FIIL mutations were more likely among patients suffering from MA. Whether biological thrombophilia screening should be systematically performed in women suffering from MA remains to be determined.
Source: Thrombosis Research - February 18, 2014 Category: Hematology Authors: L. Maitrot-Mantelet, M.H. Horellou, H. Massiou, J. Conard, A. Gompel, G. Plu-Bureau Tags: Clinical Studies Source Type: research

Mechanical heart valve prosthesis and warfarin – Treatment quality and prognosis
Conclusion: Patients with a lower warfarin treatment quality measured by TTR have a higher risk of complications such as severe bleeding or death. A TTR of 83% or higher at the individual level should be obtained for best outcome.
Source: Thrombosis Research - March 18, 2014 Category: Hematology Authors: Bartosz Grzymala-Lubanski, Ashkan Labaf, Erling Englund, Peter J. Svensson, Anders Själander Tags: Clinical Studies Source Type: research

Possible limitations of using the HAS-BLED bleeding score in real life settings
Atrial fibrillation (AF) is the most prevalent sustained arrhythmia associated with a fivefold to sevenfold increased risk of ischemic stroke. Current recommendations are to consider oral anticoagulation (OAC) for all AF patients with a CHA2DS2VASc score of 1 or higher . In conjunction with the CHA2DS2VASc score, the HAS-BLED bleeding score is recommended for use when weighing the risk of thrombosis against the risk of bleeding . Although HAS-BLED is an objective and easily remembered scoring system, I have found that it is prone to misinterpretation by end-users.
Source: Thrombosis Research - February 12, 2014 Category: Hematology Authors: Sadi Gulec Tags: Editorials Source Type: research

D-dimer relates positively with increased blood pressure in black South Africans: The SABPA study
Conclusion: The black population had a more prothrombotic profile, with higher levels of coagulation markers and inhibited fibrinolysis, than the white study participants. The positive association between blood pressure and elevated D-dimer in the blacks may contribute to the high prevalence of hypertension and related increased cardiovascular and cerebrovascular risk in this group.
Source: Thrombosis Research - April 8, 2014 Category: Hematology Authors: Leandi Lammertyn, Aletta E. Schutte, Marlien Pieters, Rudolph Schutte Tags: Coagulation and Fibrinolysis Source Type: research

Specific risk scores for specific purposes: Use CHADS-VASc for assessing stroke risk, and use HAS-BLED for assessing bleeding risk in atrial fibrillation
Source: Thrombosis Research - June 10, 2014 Category: Hematology Authors: Mikhail S. Dzeshka, Gregory Y.H. Lip Source Type: research

Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation
Source: Thrombosis Research - May 26, 2014 Category: Hematology Authors: Tereza Lanitis, Thitima Kongnakorn, Lena Jacobson, Anna De Geer Source Type: research

Blood genomic profiling in extracranial- and intracranial atherosclerosis in ischemic stroke patients
Source: Thrombosis Research - July 6, 2014 Category: Hematology Authors: Han-Bin Lee, Yoon Kim, Hanna Yoo, Ji-Min Lee, Yu-Kyung Kim, Nam-Keun Kim, Jin-Kyeoung Kim, Seung-Hun Oh Source Type: research

Lysability of fibrin clots is a potential new determinant of stroke risk in atrial fibrillation
Source: Thrombosis Research - July 5, 2014 Category: Hematology Authors: Jane Skov, Johannes J. Sidelmann, Else-Marie Bladbjerg, Jørgen Jespersen, Jørgen Gram Source Type: research

Erythropoiesis-stimulating agents and thrombotic events in dialysis patients
Erythropoiesis-stimulating agents (ESA) have been associated with a higher cardiovascular event and mortality rate in dialysis patients. The ESA-associated risk of arterial thrombotic events is mainly based on composite endpoints of anemia-correction trials targeting high hemoglobin levels. The ESA-associated risk of venous thromboembolism (VTE) has not been studied in dialysis patients yet. We therefore aimed to determine the association between ESA use and dose with ischemic stroke, myocardial infarction (MI) and VTE.
Source: Thrombosis Research - August 1, 2014 Category: Hematology Authors: Marit M. Suttorp, Tiny Hoekstra, Gürbey Ocak, Anouk T.N. van Diepen, Ilka Ott, Moshe Mittelman, Ton J. Rabelink, Raymond T. Krediet, Friedo W. Dekker Source Type: research